Statements (30)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
triptan |
| gptkbp:approvalYear |
2001 (US)
|
| gptkbp:ATCCode |
N02CC05
|
| gptkbp:brand |
Axert
|
| gptkbp:CASNumber |
154323-57-6
|
| gptkbp:contraindication |
gptkb:hemiplegic_migraine
ischemic heart disease uncontrolled hypertension |
| gptkbp:developer |
gptkb:Almirall
|
| gptkbp:drugClass |
serotonin receptor agonist
|
| gptkbp:eliminationHalfLife |
3-4 hours
|
| gptkbp:excretion |
renal
|
| gptkbp:hasMolecularFormula |
C17H25N3O2S
|
| https://www.w3.org/2000/01/rdf-schema#label |
Almotriptan
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:mechanismOfAction |
5-HT1B/1D receptor agonist
|
| gptkbp:metabolism |
hepatic
|
| gptkbp:pregnancyCategory |
C (US)
|
| gptkbp:proteinBinding |
35%
|
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
nausea
dizziness drowsiness dry mouth |
| gptkbp:synonym |
Almotriptan malate
Axert |
| gptkbp:usedFor |
migraine
|
| gptkbp:bfsParent |
gptkb:Triptans
|
| gptkbp:bfsLayer |
7
|